STOCK TITAN
  1. Home
  2. Sec-filings
  3. LAB
  4. [Form 4] STANDARD BIOTOOLS INC. Insider Trading Activity

Eli Casdin (LAB) granted RSUs and stock options, reports large fund holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin reported new equity awards and updated holdings in Form 4. He received 99,116 Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day before the company’s next annual stockholder meeting, with each RSU delivering one share of common stock upon vesting.

Casdin was also granted stock options for 175,923 shares of common stock at an exercise price of $0.8297 per share, expiring on June 18, 2036 and becoming exercisable in twelve equal monthly installments starting July 18, 2026. Following these awards, he holds 3,053,169 shares directly and has additional indirect holdings of 72,100,000 shares through Casdin Partners Master Fund, L.P., 2,744,219 shares through Casdin Private Growth Equity Fund, L.P., and 13,939,637 shares through Casdin Private Growth Equity Fund II, L.P.

Positive

  • None.

Negative

  • None.

Insights

Filing shows routine director equity awards and large existing holdings.

The Form 4 for STANDARD BIOTOOLS INC. details equity-based compensation for director and 10% owner Eli Casdin. He received 99,116 RSUs and options for 175,923 shares at an exercise price of $0.8297, both tied to continued service.

The RSUs vest in a single tranche on the earlier of June 18, 2027 or one day before the next annual meeting, while the options vest monthly beginning July 18, 2026 and expire on June 18, 2036. These terms align with typical long-term incentive structures for significant shareholders and directors.

Indirect positions through multiple Casdin-managed funds total tens of millions of shares, including 72,100,000 shares held by Casdin Partners Master Fund, L.P. This filing does not show open-market buying or selling activity; it records grants and updated beneficial ownership, so the overall impact on the investment thesis appears neutral.

Insider Casdin Eli
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 175,923 $0.00 --
Grant/Award Common Stock 99,116 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to buy) — 175,923 shares (Direct, null); Common Stock — 3,053,169 shares (Direct, null); Common Stock — 13,939,637 shares (Indirect, Casdin Private Growth Equity Fund II, L.P.)
Footnotes (1)
  1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
RSU grant 99,116 units Restricted Stock Units vesting on earlier of June 18, 2027 or pre-next annual meeting
Stock option grant 175,923 options Right to buy common stock awarded June 18, 2026
Option exercise price $0.8297/share Strike price for 175,923 stock options
Option expiration June 18, 2036 Expiration date of granted stock options
Direct holdings after award 3,053,169 shares Common stock directly held following RSU grant
Master Fund indirect holdings 72,100,000 shares Held by Casdin Partners Master Fund, L.P.
Equity Fund indirect holdings 2,744,219 shares Held by Casdin Private Growth Equity Fund, L.P.
Equity Fund II indirect holdings 13,939,637 shares Held by Casdin Private Growth Equity Fund II, L.P.
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
beneficially owned financial
"may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin")"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Stock Option (Right to buy) financial
"security_title": "Stock Option (Right to buy)""
investment adviser financial
"Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
managing member financial
"Eli Casdin, the managing member of Casdin"
indirectly beneficially owned financial
"may be deemed to be indirectly beneficially owned by (i) Casdin"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Casdin Eli
(Last)(First)(Middle)
C/O STANDARD BIOTOOLS INC.
50 MILK STREET, 10TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02109
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A99,116(1)A$03,053,169D
Common Stock13,939,637ICasdin Private Growth Equity Fund II, L.P.(2)
Common Stock2,744,219IBy Casdin Private Growth Equity Fund, L.P.(3)
Common Stock72,100,000ICasdin Partners Master Fund, L.P.(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$0.829706/18/2026A175,923 (5)06/18/2036Common Stock175,923$0175,923D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
3. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
4. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
5. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Remarks:
The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ Eli Casdin06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Eli Casdin receive in the latest STANDARD BIOTOOLS (LAB) Form 4?

Eli Casdin received 99,116 Restricted Stock Units and stock options for 175,923 shares. The RSUs vest in a single tranche, while the options carry a $0.8297 exercise price and long-dated expiration, providing equity-based compensation tied to future service.

How do the new RSUs for Eli Casdin at STANDARD BIOTOOLS (LAB) vest?

The 99,116 Restricted Stock Units vest in full on the earlier of June 18, 2027 and one day before STANDARD BIOTOOLS’ next annual stockholder meeting. Each RSU converts into one share of common stock upon vesting, contingent on Casdin’s continued service through the vesting date.

What are the terms of Eli Casdin’s new stock options in STANDARD BIOTOOLS (LAB)?

Casdin’s new stock options cover 175,923 shares of common stock at a $0.8297 exercise price. They become exercisable in twelve equal monthly installments starting July 18, 2026 and expire June 18, 2036, rewarding ongoing service over a multi-year period.

How many STANDARD BIOTOOLS (LAB) shares does Eli Casdin now hold directly?

After the reported transactions, Eli Casdin holds 3,053,169 shares of STANDARD BIOTOOLS common stock directly. This direct position sits alongside substantial indirect holdings through various Casdin-managed funds, reflecting his status as both a director and significant shareholder.

What indirect STANDARD BIOTOOLS (LAB) holdings are associated with Eli Casdin’s funds?

Indirect holdings include 72,100,000 shares through Casdin Partners Master Fund, L.P., 2,744,219 shares via Casdin Private Growth Equity Fund, L.P., and 13,939,637 shares via Casdin Private Growth Equity Fund II, L.P. These positions may be deemed indirectly beneficially owned by Casdin through advisory and management roles.

Does the Eli Casdin Form 4 for STANDARD BIOTOOLS (LAB) show open-market share purchases or sales?

The Form 4 shows equity grants and updated beneficial ownership, not open-market purchases or sales. Reported transactions are RSU and option awards with zero purchase price, plus holdings entries for large positions held indirectly through various Casdin-managed investment funds.